🇺🇸 Tandrilax in United States

246 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 246

Most-reported reactions

1. Pain — 42 reports (17.07%)
2. Arthralgia — 31 reports (12.6%)
3. Drug Ineffective — 26 reports (10.57%)
4. Fatigue — 25 reports (10.16%)
5. Pain In Extremity — 24 reports (9.76%)
6. Dyspnoea — 21 reports (8.54%)
7. Gait Disturbance — 20 reports (8.13%)
8. Headache — 20 reports (8.13%)
9. Malaise — 20 reports (8.13%)
10. Asthenia — 17 reports (6.91%)

Source database →

Frequently asked questions

Is Tandrilax approved in United States?

Tandrilax does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tandrilax in United States?

Farmoquimica S.A. is the originator. The local marketing authorisation holder may differ — check the official source linked above.